Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Amarin has promoted Karim Mikhail from senior vice president and commercial head to CEO. Mikhail previously served as CEO of Theodon.
Christopher Heery has been named chief medical officer of clinical-stage biopharmaceutical company Arcellx. Heery is the former chief medical officer at Precision Biosciences.
Stephan Stenglein, former head of late-stage development at AstraZeneca, has been named chief medical officer at Atriva Therapeutics.
Castle Creek Biosciences
Matthew Gantz has taken over Castle Creek Biosciences as its newest CEO. Gantz was formerly the CEO of OxThera AB.
Dominik Höchli has been named CEO of Catapult Therapeutics. Höchli was most recently vice president and head of global medical affairs at AbbVie.
Michael Gaffney has taken the helm of Cellphire Therapeutics as its newest CEO. Previously, Gaffney was founder and managing director of consulting business Bancroft Group.
Abraham Ceesay has been named president of Cerevel Therapeutics. Ceesay previously served as the CEO of Tiburio Therapeutics.
Isaac Klein has been named chief scientific officer at Dewpoint Therapeutics. Klein is a former researcher at the Whitehead Institute of the Massachusetts Institute of Technology.
Enveda Biosciences has hired Sotirios Karathanasis to take on the role of chief scientific officer. Karathanasis previously served as chief scientific officer at Lilly Research Laboratories.
Everest Medicines has hired Jennifer Yang to take on the position of chief scientific officer. Yang previously served as vice president and head of China for Johnson & Johnson’s Lung Cancer Initiative.
Gossamer Bio has promoted Laura Carter from senior vice president of research and translational biology to chief scientific officer.
HepaTx has tapped Salah Kivlighn to take on the role of CEO. Kivlighn previously served as senior vice president and head of global marketing at U.S. Pharmacopeia.
Humanigen has appointed Adrian Kilcoyne to chief medical officer. Previously, Kilcoyne served as vice president of oncology global medical affairs and head of evidence generation and external alliances for AstraZeneca.
Loui Madakamutil has been named chief scientific officer of ImCheck Therapeutics. Madakamutil is the former chief scientific officer of Invivoscribe Therapeutics.
Raman Singh has been named CEO at Juniper Biologics. Previously, Singh served as CEO of Mundipharma.
Kevin Moulder, former chief operating officer at PolyProx Therapeutics, has been named the new chief scientific officer of Medicenna Therapeutics.
Steven Cha, former vice president of oncology at Samumed, has been named the new chief medical officer at NKGen Biotech.
Alan List, former CEO of Moffitt Cancer Center, has been named the new chief medical officer of Precision BioSciences.
Protara Therapeutics has appointed Martín Sebastian Olivo to chief medical officer. Olivo previously served as vice president of breast cancer clinical development at Gilead Sciences.
John Boghossian has been named CEO of Quercis Pharma. Boghossian is the former director of Pangea Botanica and vice president of operations at Compass Pathways.
Sitryx has appointed Iain Kilty to chief scientific officer. Previously, Kilty was the chief scientific officer at Quench Bio.
Sutro Biopharma has promoted Trevor Hallam from chief scientific officer to president of research. Hallam served as executive vice president of research and development at Palatin Technologies prior to joining Sutro.
Tubulis has appointed Günter Fingerle-Rowson to chief medical officer. Previously, Fingerle-Rowson served as vice president at MorphoSys.